A Database Survey to Evaluate the Safety of Immune Globulin Subcutaneous (Human), 20% Solution in Participants With Primary Immunodeficiency

Recruiting now

Conditions studied: Primary Immunodeficiency Diseases (PID)

In brief

This study is a retrospective database study in Japan to evaluate the safety of Immune Globulin Subcutaneous (Human), 20% Solution in participants with primary immunodeficiency disease (PID). This survey will conduct in use of medical database called PIDJ2.

Key facts

Study ID

NCT06565078

Run by

Takeda

People needed

100

Starts

2025-02-17

Expected to finish

2030-03-31

Last updated by the study team

2026-08-07

Who can join

Age: any. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patients with primary immunodeficiency (PID) enrolled in the PID patient registry.
• Participant for whom study drug is entered in the therapeutic drug field on the data set.
• Participant who is entered the intractable disease diagnosis corresponding to PID in the intractable disease information field.
• Participant for whom the presence or absence of adverse events has been entered in the column of adverse events.

You may not qualify if…

• Participant for whom study drug has not been entered in the drug name in the medical history field during the period from January 24, 2024 to January 23, 2029.
• Participant who is not entered the intractable disease diagnosis corresponding to PID in the intractable disease information field.
• Participant for whom the presence or absence of adverse events has not been entered in the column of adverse events.

Where it is running

• Takeda selected site — Tokyo, Tokyo, Japan (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.